ScopeMed

Cover Block

Attribute	Value
Name	ScopeMed
Tagline	Modular oxygen masks for respiratory care
Headquarters	Brunswick, Ohio
Stage	Pre-Seed
Business Model	B2B
Industry	Healthtech
Technology	Hardware
Geography	North America
Growth Profile	SMB / Main Street
Founding Team	Solo Founder
Funding Label	Undisclosed

Links

• Website: https://www.scopemedicine.com
• LinkedIn: https://www.linkedin.com/company/scope-med

Summary and Signal

ScopeMed is developing modular oxygen masks designed to improve high-flow therapy and airway management in hospitals, a niche hardware bet in respiratory care. The company’s core products, the S.C.O.P.E. Respirator and O2rizon open mask, aim to reduce aerosol transmission and provide precise oxygen delivery with EtCO2 sampling, differentiating through modularity and multi-functionality within a single device [ScopeMed, Unknown]. Founder and CEO Tosan Ugbeye is a practicing Medicare-enrolled Anesthesiologist Assistant [Medicarelist, Unknown] [LinkedIn, 2026]. Capitalization is not publicly disclosed [ScopeMed, Unknown].

Data Accuracy: YELLOW -- Product claims and founder background are sourced from the company website and a limited third-party profile; funding and traction are unconfirmed.

Taxonomy Snapshot

Axis	Classification
Stage	Pre-Seed
Business Model	B2B
Industry / Vertical	Healthtech
Technology Type	Hardware
Geography	North America
Growth Profile	SMB / Main Street
Founding Team	Solo Founder
Funding	Undisclosed

Company Overview

ScopeMed operates as a medical device startup focused on respiratory care, with its headquarters listed in Brunswick, Ohio. The company's public presence centers on its website, which outlines a mission to develop modular oxygen delivery systems for clinical settings.

The founding narrative centers on Tosan Ugbeye, identified as the founder and CEO. Ugbeye is a Medicare-enrolled Anesthesiologist Assistant (AA-C) practicing in Cleveland [Medicarelist]. He attended Case Western Reserve University School of Medicine [LinkedIn, 2026]. The company's 'About Us' page mentions an individual named Iravanchy with an aerospace engineering background contributing to product development [ScopeMed].

The company holds one issued patent with others pending [ScopeMed]. It is listed as a member of MTEC, a medical technology consortium [MTEC].

Data Accuracy: YELLOW -- Core company details rely on the company's own website and LinkedIn. Founder background is partially corroborated by a Medicare listing and LinkedIn, but key operational milestones lack independent sources.

The Product and the Stack

ScopeMed’s product development centers on two core hardware devices. The S.C.O.P.E. Respirator is positioned as an aerosol-filtering mask with interchangeable caps intended to reduce particle transmission [ScopeMed]. The O2rizon is an open mask system for delivering high-flow oxygen at rates between 1 and 15 liters per minute, with an integrated EtCO2 sampling port [ScopeMed, MTEC].

Technical leadership is attributed on the company’s website to an individual with an aerospace engineering background [ScopeMed]. The company holds one issued patent with others pending [PUBLIC].

Data Accuracy: YELLOW -- Product details sourced from company website and member directory; performance claims and regulatory status lack independent corroboration.

Market Research and Opportunity

The market for advanced respiratory care devices sits at the intersection of persistent clinical needs and evolving healthcare economics. The global market for respiratory care devices was valued at approximately $19.2 billion in 2023 and is projected to grow at a compound annual growth rate of 8.5% through 2030 [Grand View Research, 2024].

Metric	Value
Global Respiratory Care Devices Market (2023)	$19.2B
Projected CAGR (2023-2030)	8.5%

Data Accuracy: YELLOW -- Market sizing is from a third-party report for an analogous category; company-specific TAM/SAM/SOM and regulatory status are not publicly available.

The Competitive Field

ScopeMed's competitive position is defined by its attempt to carve a niche within the mature and heavily consolidated market for respiratory therapy hardware. Incumbents include Medtronic, Philips, and GE Healthcare. Specialized respiratory-focused manufacturers like Vapotherm, Fisher & Paykel Healthcare, and Armstrong Medical represent the most direct competitive set.

ScopeMed claims a defensible edge in its specific product architecture, the modularity and multi-functionality of its S.C.O.P.E. Respirator and O2rizon mask [ScopeMed, Unknown]. This product-level innovation, protected by one issued patent with others pending, constitutes its primary technical moat.

Data Accuracy: ORANGE -- Competitive mapping is inferred from the broader market; specific claims about ScopeMed's products are sourced solely from its website without independent validation.

Opportunity

ScopeMed is addressing a tangible clinical need with a hardware-focused, patent-protected approach. The products are designed to solve specific problems in respiratory care: reducing aerosol transmission for providers and preventing unnecessary intubations through better EtCO2 monitoring [ScopeMed, Unknown].

Scenario	What happens	Catalyst	Why it's plausible
Niche Dominance in Procedural Settings	ScopeMed becomes the standard-of-care mask for bronchoscopy, endoscopy, and other aerosol-generating procedures in U.S. outpatient surgery centers.	A key opinion leader (KOL) in gastroenterology or pulmonology publishes a peer-reviewed study validating the S.C.O.P.E. Respirator's efficacy in reducing particulate exposure.	The product is explicitly designed for "aerosol-filtering" in procedural settings [ScopeMed, Unknown]. Founder Tosan Ugbeye's clinical network provides a potential conduit for initiating such a study [HJK Digital, Unknown].
Regulatory Pathway to Standardization	The O2rizon's integrated EtCO2 sampling capability leads to its inclusion in clinical guidelines for managing patients at risk of respiratory failure, driving adoption across emergency departments and ICUs.	The company secures a 510(k) clearance from the FDA that specifically highlights the clinical utility of its passive monitoring feature.	The company claims to have one patent issued and multiple pending, indicating a focus on intellectual property that could support a regulatory filing [Perplexity Sonar Pro Brief].

Data Accuracy: YELLOW -- Product claims and founder background are sourced from the company website and a limited third-party profile; market context is inferred from a general AI brief. No independent validation of commercial progress exists.

Sources

1. [ScopeMed, Unknown] ABOUT US | ScopeMed | https://www.scopemedicine.com/about-us
2. [LinkedIn, 2026] Tosan Ugbeye - Scope Med | LinkedIn | https://www.linkedin.com/in/tosan-ugbeye-76085a47/
3. [Medicarelist, Unknown] Tosan Amuyirigbortise Ugbeye, AA-C in Cleveland, OH - Medicare | https://www.medicarelist.com/nurse/amuyirigboritse-tosan-ugbeye-cleveland-oh/
4. [HJK Digital, Unknown] Tech Talks: Disrupting Healthcare with Tosan Ugbeye, Founder and CEO of ScopeMed | https://www.hjkdigital.com/post/tech-talks-disrupting-healthcare-with-tosan-ugbeye-founder-of-scopemed
5. [LinkedIn] ScopeMed | LinkedIn | https://www.linkedin.com/company/scope-med
6. [MTEC] Scopemed | MTEC | https://mtec-sc.org/members/scopemed
7. [ScopeMed, Unknown] INVESTORS | ScopeMed | https://www.scopemedicine.com/investors
8. [Perplexity Sonar Pro Brief] Perplexity Sonar Pro Brief |
9. [Grand View Research, 2024] Global Respiratory Care Devices Market Report |
10. [Reuters, 2021] Vyaire Medical Acquisition |